1. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive <br />early breast cancer (EBC)
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

2. TARGETING HER2 IN BREAST CANCER: EVOLVING CONCEPTS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

3. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 3
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

4. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 4
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

5. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 5
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

6. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 6
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

7. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 7
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

8. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Primary Endpoint
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

9. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
SECONDARY EndpointS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

10. STAtiStical considerations
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

11. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Current Analysis Plan
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

12. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 12
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

13. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
CONSORT TABLE
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

14. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 14
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

15. Distribution of the Stratification Factors by Treatment Arm
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

16. Distribution of patient characteristics by Treatment Arm
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

17. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 17
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

18. DISEASE-FREE SURVIVAL (DFS) ANALYSIS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

19. DFS BY Hormone Receptor Status
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

20. DFS by Chemotherapy Timing
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

21. OVERALL SURVIVAL (OS) ANALYSIS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

22. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
DFS NON-INFERIORITY ANALYSIS<br />Note: Null hypothesis hazard ratio is 1.11
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

23. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 23
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

24. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
PROPORTION OF PATIENTS RECEIVING ≥ 85% OF THE PLANNED DOSE OF ANTI-HER2 DRUGS
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

25. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 25
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

26. MAIN DIFFERENCES IN AEs BY TREATMENT ARM
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

27. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
CARDIAC SAFETY
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

28. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
CONCLUSIONS (I)
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

29. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
CONCLUSIONS (II)
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

30. Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Acknowledgements
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting